ArticleBriefings in bioinformatics2025
Dynamic changes of synergy relationship between lncRNA and immune checkpoint in cancer progression.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In the battle between tumors and the immune system, immune evasion based on immune checkpoints (ICPs) is a critical mechanism for tumor progression. Long noncoding RNAs (lncRNAs) are key players in tumorigenesis and immune responses; however, the mechanisms underlying the synergistic relationship between lncRNAs and ICPs in cancer progression remain poorly understood. Manually curated ICPs and high-confidence lncRNA-messenger RNA (mRNA) interactions were integrated via a protein-protein interaction (PPI) network to construct an initial set of lncRNA-ICP pairs. Stage-specific synergy scores were then performed and used to identify stage-specific synergistic pairs for each cancer type. Our findings indicate that several key genes, including MALAT1 and CRNDE, are widely involved in cancer progression and exhibit various patterns in multiple cancers. Genes within the lncRNA-ICP synergy network were associated with the dynamic changes of immune cells during cancer progression, and these relationships remain relatively stable across different cancers and stages. The relationships of the synergistic pairs we identified demonstrate consistency with spatial transcriptomics data in skin cutaneous melanoma. Notably, the overall expression of genes identified in Stage 4 could significantly differentiate patients' survival outcomes. Moreover, the genes we identified could distinguish patients' responses to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.